ACMPR Licensed Producer
CSE: HUGE
OTC: FSDDDF
FRA: 0K9

Investor Presentation
August 2018
Forward Looking Statement

This presentation and the information contained herein are confidential and the property of FSD Pharma Inc. ("FSD Pharma"). This presentation is intended to introduce you to FSD Pharma. The information presented is not, and is not intended to be, an offer to sell or the solicitation of an offer to buy any security of FSD Pharma. It does not constitute an offer, solicitation or sale of any securities of FSD Pharma. It is not a prospectus or an offering memorandum.

Statements made are as of the date hereof; delivery of this presentation does not at any time create an implication that the information contained herein is accurate as of any date subsequent to today’s date. FV Pharma has not undertaken any independent verification of industry data, trends, or third party information used herein.

This presentation contains forward looking information. These statements relate to future events, estimates, plan, expectations, forecasts, projections and future performance. Forward-looking statements are based on the opinions and assumptions of management as of the date made, and are subject to a variety of risks and other factors that could cause actual events/results to differ materially from these forward looking statements. Although management believes that the expectations are reasonable, there can be no assurance that such expectations will prove to be correct; these statements are no guarantee of future performance and involve known and unknown risks, uncertainties and other factors. We cannot guarantee future results, performance, or achievements and no representations are made that actual results achieved will be the same. Nothing herein can be assumed or predicted, and readers are strongly encouraged to learn more and seek independent advice before relying on any information presented.
Management’s Mission

To Become The Largest Hydroponic Indoor Cannabis Facility In The World
## Overview

<table>
<thead>
<tr>
<th>Health Canada ACMPR Licensed Producer (as of October 2017)</th>
<th>Current Cultivation</th>
<th>Phase 1 Expansion Target: Total - 820,000 sq.ft.</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ 35 Million Cash and Liquid Securities</td>
<td>Joint Venture With Auxly Cannabis Group Inc. (TSX.V:XLY)</td>
<td>Phase 2 Expansion Target: Total - 3,896,000 sq.ft.</td>
</tr>
<tr>
<td>No Debt</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# How The Cannabis Giants Began

<table>
<thead>
<tr>
<th>Company</th>
<th>Market Cap</th>
<th>Production Space</th>
<th>Location</th>
<th>Travel Time To Toronto</th>
</tr>
</thead>
<tbody>
<tr>
<td>HERSHEY’S</td>
<td>$11.397 Billion</td>
<td>2,800,000 sq. ft.</td>
<td>Smith’s Falls</td>
<td>3hrs 40mins</td>
</tr>
<tr>
<td>HEINZ</td>
<td>$2.587 Billion</td>
<td>301,000 sq. ft.</td>
<td>Leamington</td>
<td>3hrs 30mins</td>
</tr>
<tr>
<td>KRAFT</td>
<td>~$217 Million</td>
<td>820,000 sq. ft.</td>
<td>Cobourg</td>
<td>1 hour</td>
</tr>
</tbody>
</table>

Source: Canopy, Aphria and FSD Pharma – Market Cap: TMX Money as of August 23, 2018
Location Is The Key

Ontario’s Feel Good Town - Only 1 hour drive east of Toronto
This is “HUGE”
The company is publicly traded under the symbol "HUGE" on the CSE

<table>
<thead>
<tr>
<th>Former food grade facility 100% Owned</th>
<th>Located off the 401 Highway in Cobourg, 1 hour east of Toronto</th>
</tr>
</thead>
<tbody>
<tr>
<td>All under one roof to promote lower cost and economies of scale</td>
<td>70-acre parcel of land</td>
</tr>
<tr>
<td></td>
<td>27 acre – Plant</td>
</tr>
<tr>
<td></td>
<td>5 acre – Parking Lot</td>
</tr>
<tr>
<td></td>
<td>38 acre – Expansion Land</td>
</tr>
</tbody>
</table>
Cost Is King

• Maintaining tight costs is critical - having everything under one roof allows for:
  • greater economies of scale
  • less logistical issues

• Facility is only one hour from Toronto with major transportation access points

• Current building infrastructure valued at a replacement cost of $78 Million as per appraisal
Railway line into the facility, capacity for 3 rail cars to come inside the plant

Area to build helipad – 15 minutes to downtown

Zoned Industrial

70 Acres
Large Scale Power On Site

- Electrical substation on site with 77000 Volts line coming to the plant
- Distributed in a bank of 3 independent subs of 13800 KVA each
- Can power over 9,000 x 1,000 watt grow bulbs
- Multiple natural Gas lines on site (allows cogeneration)
State Of The Art Facilities On Site

- 26 Loading docks
- Security fences in place
- 2 separate major water manes into the facility
- 24 inch main sewage pipe
Why Indoor Cannabis is Better than Greenhouse Cannabis

- In Recreational United States, the same strain that is grown by the same grower receives higher revenue per pound.
- Greenhouse flower will mainly be used to produce oils.
- Management margins for proper indoor grown cannabis will be higher than greenhouse over the next 3 years.
- Allows production quality and consistency 365 days per year while mitigating seasonal risks.
- There are no indoor grow competitors in Canada with nearly the same size footprint and there won’t be.
# Capacity To Meet Growing Demand

<table>
<thead>
<tr>
<th></th>
<th>Current</th>
<th>Expansion 1</th>
<th>Expansion 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Facility (Sq.ft.)</td>
<td>25,000 Sq.ft.</td>
<td>820,000 Sq.ft.</td>
<td>3,896,000 Sq.ft.</td>
</tr>
<tr>
<td>Production Capacity</td>
<td>4,000 kg</td>
<td>Unlimited license</td>
<td>Unlimited license</td>
</tr>
</tbody>
</table>
## Comparable Companies

### Market Capitalization As Of August 23, 2018

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Canopy</td>
<td>WEED</td>
<td>$11,397 MM</td>
<td>2,800,000</td>
<td>6,000,000</td>
</tr>
<tr>
<td>Emerald</td>
<td>EMH</td>
<td>$649 MM</td>
<td>625,000</td>
<td>1,425,000</td>
</tr>
<tr>
<td>Cannttrust</td>
<td>TRST</td>
<td>$852 MM</td>
<td>550,000</td>
<td>1,150,000</td>
</tr>
<tr>
<td>Aphria</td>
<td>APH</td>
<td>$2,587 MM</td>
<td>300,000</td>
<td>1,000,000</td>
</tr>
<tr>
<td>Aurora</td>
<td>ACB</td>
<td>$7,561 MM</td>
<td>240,000</td>
<td>4,505,000</td>
</tr>
<tr>
<td>Maricann</td>
<td>MARI</td>
<td>$257 MM</td>
<td>217,000</td>
<td>852,000</td>
</tr>
<tr>
<td>Organigram</td>
<td>OGI</td>
<td>$693 MM</td>
<td>173,000</td>
<td>473,000</td>
</tr>
<tr>
<td>Supreme</td>
<td>FIRE</td>
<td>$382 MM</td>
<td>40,000</td>
<td>342,000</td>
</tr>
<tr>
<td>ABcann</td>
<td>ABCN</td>
<td>$190 MM</td>
<td>15,000</td>
<td>165,000</td>
</tr>
<tr>
<td>FSD Pharma</td>
<td>HUGE</td>
<td>$217 MM</td>
<td>25,000</td>
<td>3,896,000</td>
</tr>
</tbody>
</table>

*Source: TMX Money as of August 23, 2018*
Joint Venture With Auxly Cannabis Group Inc. (TSX.V:XLY)

- XLY will 100% finance and construct the buildout of the former Kraft Facility with 55 million approved in Phase 1 development budget
- FV Pharma will operate and recover all costs plus 10%
- FV Pharma will receive 50.1% of all production
- Expected allocation will result in 200M Grams of Cannabis per annum for FV Pharma’s Benefit (subject to full-capacity being achieved)
- Blue print rendering for first 220,000 sq. ft. now complete and expected to break ground in Q3 2018 with production by Jan 2019
- XLY to bring Management Expertise in:
  - Design, Development, Financing and Operations

Source: Global Newswire
More “Joint” Venture Deals In The Pipeline
Strategic Investment:

Cannara Biotech Inc.

• FV Pharma owns 25% of Cannara and will occupy over 105,000 square feet of Cannara’s 625,000 square foot facility, which sits on 27 acres of land
• Combined grow space of over 1.245 million square feet of indoor capacity
• Under way in the application process under the ACMPR and plans to be the largest indoor cultivation facility in Quebec
• Existing facility less than one hour drive from Montreal (Quebec’s largest city)
• Please see more at http://cannara.ca/about/
Strategic Investment:

High-Tide Ventures

• A fully integrated retail distribution company
• Has applied for 31 retail cannabis permits in Alberta, with application expected to be submitted for British Columbia shortly
• Owns 4 of Canada’s most prominent retail brands: RGR Canada Inc., Smokers Corner (largest chain of cannabis accessory stores in Canada), Canna Cabana, and subject to shareholder approval, will own Famous Brandz
• Please see more information on High-Tide Ventures at www.hightideventures.ca
Strategic Alliance:

SciCann Therapeutics

- SciCann Therapeutics is a Canadian-Israeli specialty pharmaceutical company, dedicated to the development and commercialization of novel and disruptive pharmaceutical products.
- FSD Pharma Inc.’s wholly-owned subsidiary, FV Pharma Inc., will invest up to $3M for a 15% equity stake in SciCann.
  - With this, FV Pharma will receive an exclusive license in Canada for the production and distribution of a line of proprietary cannabinoid-based, patent pending and indication-specific products developed by SciCann.
- Dr. Zohar Koren, co-founder and CEO of SciCann has been appointed Head of Scientific Advisory Board
- Please see more on SciCann at https://scicann.net/
Technology

- Testing new world class lighting technology which could:
  - Lower energy costs and heat produced
- Food grade facility built to better deal with bug problems
- Novel technologies to deal with:
  - Bacteria
  - Mould, Mildew
  - Virus and VOC
Industry Developments


• FSD Pharma will model its business plan after Big Pharma – focus on tight cost controls and economies of scale.
Approx. $53M Equity Capital Raised

- Raised exclusively through First Republic Capital Corp.
- Widely held with over 4,700 shareholders pre go public
- Raised all through individual accredited investors, not a single institutional investor
“HUGE” Catalysts

• Commenced trading on CSE May 2018 and has broken the Canadian all-time trading volume records for daily, weekly and monthly volumes on the CSE
• Currently growing cannabis in the facility
• FSD Pharma and SciCann Therapeutics Launch Clinical Research Program in Israel
• Break ground on 220,000 sq. ft. expansion with XLY expected Q3 2018
• Joint ventures for diversified products and distribution
• Recreational legalization fall of 2018
• Reach full production capacity in 2020
## Capital Structure

<table>
<thead>
<tr>
<th>Securities</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issued and Outstanding Basic:</td>
<td>1,319,600,458</td>
</tr>
<tr>
<td>Issued and Outstanding F/D:</td>
<td>1,531,842,915</td>
</tr>
</tbody>
</table>
TEAM

• Thomas Fairfull, CEO, President and Executive Director
• Michael Ash, Chief Commercial Officer
• Zeeshan Saeed, Executive Vice President and Director
• Anthony Durkacz, Director
• Donal Caroll, CPA, Director
• Gerald Goldberg, CPA, CA, Director
• Vladimir Klacar, Director
• Dr. Raza Bokhari, Director
• Dr. Zohar Koren, Head of Scientific Advisory Board
• Sandy Huard, Head of Investor Relations
For more information, please contact:
Investor Relations
ir@fsdpharma.com
www.fsdpharma.com
CSE: HUGE
OTC: FSDDF
FRA: 0K9